Am J Perinatol
DOI: 10.1055/a-2729-1189
Original Article

Fetal Heart Rate Tracings and Adverse Outcomes among Term Small versus Appropriate for Gestational Age

Authors

  • Shareen Patel

    1   Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States
  • Kristen A. Cagino

    1   Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States
  • Aaron W. Roberts

    1   Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States
  • Rachel L. Wiley

    2   Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego, California, United States
  • Christina Cortes

    1   Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States
  • Fabrizio Zullo

    3   Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Rome, Italy
  • Hector Mendez-Figueroa

    1   Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States
  • Suneet P. Chauhan

    4   Delaware Center for Maternal Fetal Medicine of ChristianaCare, Newark, Delaware, United States

Funding Information The authors report no financial support or external funding.

Abstract

Objective

This study aimed to compare the patterns of fetal heart rate tracings (FHRTs), and outcomes among individuals with small (birth weight [BW] <10% for gestational age [GA]; SGA) versus appropriate (BW at 10–89% for GA; AGA) newborns at term (≥37.0 weeks).

Study Design

Our retrospective cohort study included consecutive deliveries over 15 months at a level IV center. FHRTs were reviewed by obstetricians blinded to maternal and neonatal outcomes. The inclusion criteria were non-anomalous singletons, cataloged as SGA or AGA birth weight using Alexander et al's nomogram. In 20-minute segments, the last 120 minutes of tracing were characterized. Rates of cesarean delivery (CD) and composite neonatal adverse outcomes (CNAOs) were compared.

Results

Of 5,160 deliveries, 3,029 (58.7%) met the inclusion criteria, and among them, 422 (13.9%) were SGA and 2,607 (86.1%) AGA. There were no differences in FHRT baseline, variability, or accelerations. Compared to AGA, SGA was more likely to have prolonged decelerations (11.8 vs. 8.4%, p = 0.021), and recurrent decelerations with ≥50% of contractions (21.3 vs. 16.5%, p = 0.014). Overall, the presence of category II FHRT or not was similar between the SGA (91.2%) and AGA (88.5%; p = 0.097). Persistent category II FHRT was significantly more common among SGA (37.4%) than AGA (28.1%; aOR = 1.47; 95% CI: 1.47–1.82) newborns. The rate of CD for non-reassuring FHRT was similar among the two groups. CNAO occurred in 1.4% in both SGA and AGA neonates (p = 0.95).

Conclusion

In our cohort of those with fetal monitoring prior to delivery at ≥37 weeks, persistent category II FHRT at the end of labor was significantly more common in SGA compared to AGA neonates; however, composite neonatal morbidity did not differ between the two groups. Our analysis provides data for shared decision-making that among SGA newborns, abnormalities of FHRT are not linked with adverse outcomes.

Key Points

  • There were no differences in FHRT baseline, variability, or accelerations between AGA and SGA.

  • SGA was more likely to have prolonged decelerations and recurrent decelerations with ≥50% of contractions.

  • Persistent category II FHRT before delivery is significantly more common with SGA than AGA.

  • FHRT abnormalities, however, were not associated with CD for non-reassuring FHRT, or adverse outcomes.

Note

This study was presented at the SMFM 2025 January 30 to February 1 in Denver, Colorado, United States.




Publication History

Received: 28 August 2025

Accepted: 21 October 2025

Accepted Manuscript online:
24 October 2025

Article published online:
06 November 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA